Prospective Prostate Cancer Infrastructure

Starting soon

Conditions studied: High Risk Localized Prostate Cancer, Synchronous Metastatic Hormone-Sensitive Prostate Cancer

In brief

The goal of this observational study is to collect detailed long-term real-world data and biomaterials from men with high-risk localized prostate cancer and synchronous metastatic hormone-sensitive prostate cancer. This will help to better understand how these patients are treated in daily practice, how treatments affect quality of life, and facilitate biomarker discovery. The infrastructure is also designed to enable future cohort multiple randomized controlled trials.

Key facts

Study ID

NCT07560748

Run by

Radboud University Medical Center

People needed

700

Starts

2026-05-01

Expected to finish

2030-05-01

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of either: high-risk localized prostate cancer (any of the following: PSA > 20 ng/mL, ISUP Grade Group 4 or 5, or clinical stage ≥ T2c); or metastatic prostate cancer confirmed by imaging (CT, bone scintigraphy, PSMA PET/CT, or (whole-body) MRI in combination with tumor markers (PSA)), or by biopsy of a metastatic lesion histopathologically deemed to be of prostatic origin.
• Prostate adenocarcinoma (our main focus). We will allow the inclusion of adenocarcinoma with mixed small- or large-cell neuroendocrine prostate
• Age ≥ 18 years at the time of inclusion.
• Written informed consent
• Able to understand one of the following languages sufficiently: Dutch, English, Arabic or Turkish.

You may not qualify if…

• Not currently living in the Netherlands.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.